PHASE 2 STUDY DESIGN EVALUATING EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ANTI-CD40 MONOCLONAL ANTIBODY CFZ533 (ISCALIMAB) IN DE NOVO LIVER TRANSPLANT RECIPIENTS: THE CONTRAIL I STUDY. Issue 3 (September 2020) - Nashan, Björn; Knechtle, Stuart J.; Saliba, Faouzi; Laessing, Ute; Espie, Pascal; Klatt, Jan; Feng, Sandy